Table 1 Patient characteristics
From: Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
| No. of patients (%) | ||
|---|---|---|
| PBC | MBC | |
| Variables | (N = 9) | (N = 57) |
| Age at biopsy | ||
| Median (range) | 56 (31–68) | 58 (31–95) |
| Primary clinical stage | ||
| I | 2 (22.2) | 22 (38.6) |
| II | 6 (66.7) | 17 (29.8) |
| III | 1 (11.1) | 8 (14) |
| IV | 0 | 10 (17.5) |
| Histological type | ||
| Invasive ductal | 9 (100) | 53 (93) |
| Invasive lobular | 0 | 3 (5.3) |
| Mucinous | 0 | 1 (1.8) |
| Histological grade | ||
| 1 | 6 (66.7) | 10 (17.5) |
| 2 | 2 (22.2) | 27 (47.4) |
| 3 | 1 (11.1) | 17 (29.8) |
| Lobular | 0 | 3 (5.2) |
| Median percentage of ERα (25%, 75%) | 90 (75, 92.5) | 85 (70, 90) |
| Median percentage of PgR (25%, 75%) | 10 (5, 45) | 30 (5, 60) |
| HER2 | ||
| Positive | 0 | 5 (8.7) |
| Negative | 9 (100) | 52 (91.2) |
| Presence of ESR1 LBD mutations | ||
| Yes | 0 | 11 (19.3) |
| No | 9 (100) | 46 (80.7) |
| Number of metastatic organs | ||
| Median (range) | 2 (1–5) | |
| Visceral involvement | ||
| Yes | 28 (49.1) | |
| No | 29 (50.9) | |
| Metastatic lesions biopsied | ||
| Breast | 9 (15.8) | |
| Skin | 19 (33.3) | |
| Lymph Nodes | 14 (24.6) | |
| Bone | 4 (7.0) | |
| Lung | 3 (5.2) | |
| Liver | 4 (7.0) | |
| Brain | 3 (5.2) | |
| Ovary | 1 (1.8) | |
| Number of rounds of prior endocrine therapy | ||
| Median (range) | 2 (0–6) | |
| Number of rounds of prior chemotherapy | ||
| Median (range) | 0 (0–6) | |